BlackRock’s Champions Oncology CSBR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $800K | Buy |
129,848
+5,948
| +5% | +$35.9K | ﹤0.01% | 4427 |
|
|
2026
Q1 | $712K | Buy |
123,900
+1,129
| +0.9% | +$7.17K | ﹤0.01% | 4439 |
|
|
2025
Q4 | $848K | Buy |
122,771
+861
| +0.7% | +$5.73K | ﹤0.01% | 4349 |
|
|
2025
Q3 | $789K | Buy |
121,910
+1,081
| +0.9% | +$7.62K | ﹤0.01% | 4361 |
|
|
2025
Q2 | $891K | Buy |
120,829
+4,970
| +4% | +$35.1K | ﹤0.01% | 4289 |
|
|
2025
Q1 | $1.01M | Sell |
115,859
-441
| -0.4% | -$4.47K | ﹤0.01% | 4185 |
|
|
2024
Q4 | $997K | Buy |
116,300
+109
| +0.1% | +$548 | ﹤0.01% | 4219 |
|
|
2024
Q3 | $566K | Buy |
116,191
+119
| +0.1% | +$558 | ﹤0.01% | 4295 |
|
|
2024
Q2 | $600K | Buy |
116,072
+389
| +0.3% | +$1.9K | ﹤0.01% | 4297 |
|
|
2024
Q1 | $567K | Sell |
115,683
-414
| -0.4% | -$2.42K | ﹤0.01% | 4339 |
|
|
2023
Q4 | $652K | Sell |
116,097
-200
| -0.2% | -$1.12K | ﹤0.01% | 4361 |
|
|
2023
Q3 | $722K | Sell |
116,297
-842
| -0.7% | -$5.32K | ﹤0.01% | 4331 |
|
|
2023
Q2 | $747K | Buy |
117,139
+1,292
| +1% | +$6.67K | ﹤0.01% | 4367 |
|
|
2023
Q1 | $466K | Sell |
115,847
-6,211
| -5% | -$26.5K | ﹤0.01% | 4543 |
|
|
2022
Q4 | $550K | Sell |
122,058
-78
| -0.1% | -$510 | ﹤0.01% | 4583 |
|
|
2022
Q3 | $916K | Sell |
122,136
-1,223
| -1% | -$10.2K | ﹤0.01% | 4507 |
|
|
2022
Q2 | $988K | Buy |
123,359
+561
| +0.5% | +$4.29K | ﹤0.01% | 4538 |
|
|
2022
Q1 | $999K | Sell |
122,798
-648
| -0.5% | -$5.19K | ﹤0.01% | 4665 |
|
|
2021
Q4 | $1.03M | Buy |
123,446
+1,048
| +0.9% | +$9.65K | ﹤0.01% | 4656 |
|
|
2021
Q3 | $1.25M | Buy |
122,398
+15,376
| +14% | +$156K | ﹤0.01% | 4499 |
|
|
2021
Q2 | $1.1M | Sell |
107,022
-363,425
| -77% | -$3.68M | ﹤0.01% | 4488 |
|
|
2021
Q1 | $5.32M | Buy |
470,447
+4,988
| +1% | +$57.9K | ﹤0.01% | 3919 |
|
|
2020
Q4 | $5.02M | Buy |
465,459
+15,447
| +3% | +$159K | ﹤0.01% | 3706 |
|
|
2020
Q3 | $4.16M | Buy |
450,012
+14,384
| +3% | +$128K | ﹤0.01% | 3646 |
|
|
2020
Q2 | $4.17M | Buy |
435,628
+287,677
| +194% | +$2.45M | ﹤0.01% | 3597 |
|
|
2020
Q1 | $1.09M | Buy |
147,951
+6,374
| +5% | +$44.6K | ﹤0.01% | 3840 |
|
|
2019
Q4 | $1.18M | Buy |
141,577
+4,214
| +3% | +$26K | ﹤0.01% | 3954 |
|
|
2019
Q3 | $776K | Buy |
137,363
+336
| +0.2% | +$2.18K | ﹤0.01% | 4064 |
|
|
2019
Q2 | $1.07M | Buy |
137,027
+14,733
| +12% | +$129K | ﹤0.01% | 3983 |
|
|
2019
Q1 | $1.2M | Sell |
122,294
-2,717
| -2% | -$27.1K | ﹤0.01% | 3856 |
|
|
2018
Q4 | $976K | Buy |
125,011
+1,471
| +1% | +$16.9K | ﹤0.01% | 3893 |
|
|
2018
Q3 | $2.16M | Buy |
123,540
+107,202
| +656% | +$955K | ﹤0.01% | 3753 |
|
|
2018
Q2 | $104K | Buy |
+16,338
| New | +$78.5K | ﹤0.01% | 4456 |
|
Other funds holding CSBR
TAM
MBAM
BlackRock's CSBR Position: Q2 2026 in Review
BlackRock increased its Champions Oncology (CSBR) stake by 4.8% in Q2 2026, buying an estimated $35.9K and bringing the position to 129,848 shares worth $800K. The position accounts for ﹤0.01% of the portfolio, ranked #4427.
BlackRock first reported a position in CSBR in Q2 2018 and has held it in 33 quarters since. The position peaked at $5.32M in Q1 2021. 23 funds tracked by Wall St. Rank hold CSBR as of Q2 2026.
- BlackRock held 129,848 shares of Champions Oncology worth $800K as of Q2 2026.
- BlackRock bought 5,948 Champions Oncology shares in Q2 2026, an estimated $35.9K.
- Champions Oncology made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4427 holding.
- BlackRock first reported a position in Champions Oncology in Q2 2018 and has held it in 33 quarters since.
- BlackRock's Champions Oncology position peaked at $5.32M in Q1 2021.
- 23 funds tracked by Wall St. Rank held Champions Oncology as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.